[Correspondence] BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas

AI Summary

Recent advances in CAR T-cell therapies targeting CD19 have improved treatment options for relapsed or refractory B-cell lymphomas, though disease progression remains a challenge. Resistance mechanisms such as antigen escape prompt exploration of CD20/CD3 bispecific antibodies to improve long-term outcomes.

Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have transformed the treatment options for relapsed and refractory B-cell non-Hodgkin lymphoma, yet many patients eventually have disease progression, with poor outcomes following treatment failure. Antigen escape, including loss or downregulation of CD19, is a key mechanism of resistance, occurring in 20–30% of cases.1 Although T-cell-engaging CD20/CD3 bispecific antibodies have expanded available treatment options, long-term outcomes in patients who have progressed after CAR T-cell therapy remain modest and are still being characterised.